Barclays’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.5M Sell
426,256
-31,773
-7% -$2.92M 0.01% 820
2025
Q4
$41.2M Sell
458,029
-31,027
-6% -$2.94M 0.01% 877
2025
Q3
$48.2M Sell
489,056
-34,741
-7% -$3.44M 0.01% 790
2025
Q2
$47.8M Sell
523,797
-40,379
-7% -$3.9M 0.01% 728
2025
Q1
$63.9M Buy
564,176
+89,223
+19% +$9.54M 0.02% 568
2024
Q4
$50.2M Sell
474,953
-174,820
-27% -$18.8M 0.01% 662
2024
Q3
$70.1M Sell
649,773
-51,587
-7% -$5.63M 0.02% 557
2024
Q2
$76.1M Sell
701,360
-17,372
-2% -$2.05M 0.02% 482
2024
Q1
$94.9M Buy
718,732
+10,146
+1% +$1.27M 0.03% 395
2023
Q4
$86.2M Sell
708,586
-363,908
-34% -$40.6M 0.03% 461
2023
Q3
$120M Buy
1,072,494
+604,652
+129% +$76.8M 0.08% 255
2023
Q2
$68.1M Buy
467,842
+220,328
+89% +$29.9M 0.04% 364
2023
Q1
$32M Sell
247,514
-69,680
-22% -$8.75M 0.01% 654
2022
Q4
$40.4M Buy
317,194
+46,366
+17% +$5.38M 0.02% 582
2022
Q3
$28.3M Buy
270,828
+52,971
+24% +$5.81M 0.03% 489
2022
Q2
$22.9M Sell
217,857
-275,926
-56% -$32.7M 0.01% 668
2022
Q1
$63.2M Sell
493,783
-155,115
-24% -$18.7M 0.05% 351
2021
Q4
$80M Buy
648,898
+1,145
+0.2% +$150K 0.03% 417
2021
Q3
$92M Buy
647,753
+51,873
+9% +$7.63M 0.04% 343
2021
Q2
$93M Buy
595,880
+11,224
+2% +$1.82M 0.04% 316
2021
Q1
$90.9M Buy
584,656
+113,943
+24% +$17.6M 0.05% 278
2020
Q4
$70.4M Buy
470,713
+33,656
+8% +$4.75M 0.04% 350
2020
Q3
$57.8M Buy
437,057
+32,848
+8% +$4.29M 0.03% 360
2020
Q2
$46.8M Sell
404,209
-11,996
-3% -$1.38M 0.04% 350
2020
Q1
$40.8M Sell
416,205
-215,378
-34% -$28.2M 0.03% 369
2019
Q4
$91.8M Sell
631,583
-71,102
-10% -$9.81M 0.05% 288
2019
Q3
$93.7M Sell
702,685
-216,246
-24% -$27.9M 0.06% 266
2019
Q2
$105M Buy
918,931
+33,422
+4% +$3.91M 0.06% 252
2019
Q1
$110M Buy
885,509
+153,319
+21% +$17.4M 0.08% 209
2018
Q4
$73.7M Sell
732,190
-42,259
-5% -$4.75M 0.06% 253
2018
Q3
$98.8M Buy
774,449
+46,266
+6% +$5.5M 0.07% 209
2018
Q2
$78.8M Sell
728,183
-140,682
-16% -$15.3M 0.07% 240
2018
Q1
$92M Buy
868,865
+232,142
+36% +$27M 0.07% 234
2017
Q4
$74.6M Buy
636,723
+175,992
+38% +$19.9M 0.06% 263
2017
Q3
$52.4M Sell
460,731
-19,517
-4% -$2.25M 0.05% 281
2017
Q2
$59.9M Buy
480,248
+34,708
+8% +$4.11M 0.06% 234
2017
Q1
$52.8M Buy
445,540
+198,619
+80% +$22.5M 0.06% 237
2016
Q4
$24.7M Sell
246,921
-57,741
-19% -$6.19M 0.03% 507
2016
Q3
$38.5M Sell
304,662
-114,998
-27% -$14.2M 0.04% 312
2016
Q2
$49M Sell
419,660
-189,287
-31% -$21.4M 0.06% 264
2016
Q1
$62.7M Buy
608,947
+248,434
+69% +$24M 0.1% 168
2015
Q4
$35.7M Sell
360,513
-5,643
-2% -$552K 0.04% 370
2015
Q3
$33.1M Sell
366,156
-7,697
-2% -$772K 0.04% 398
2015
Q2
$39.6M Sell
373,853
-42,278
-10% -$4.68M 0.04% 375
2015
Q1
$47.3M Buy
416,131
+59,863
+17% +$6.83M 0.05% 347
2014
Q4
$39.1M Sell
356,268
-23,873
-6% -$2.52M 0.04% 442
2014
Q3
$36.9M Buy
380,141
+208,345
+121% +$20.5M 0.04% 435
2014
Q2
$17.2M Sell
171,796
-10,255
-6% -$1M 0.02% 790
2014
Q1
$16.6M Sell
182,051
-651,928
-78% -$60.1M 0.02% 808
2013
Q4
$75.3M Buy
833,979
+617,083
+285% +$53.4M 0.08% 225
2013
Q3
$17.3M Buy
216,896
+19,693
+10% +$1.55M 0.02% 765
2013
Q2
$14.3M Buy
+197,203
New +$14.7M 0.02% 831

Other funds holding ZBH

Barclays's ZBH Position: Q1 2026 in Review

Barclays reduced its Zimmer Biomet (ZBH) stake by 6.9% in Q1 2026, selling an estimated $2.92M and leaving 426,256 shares worth $38.5M. The position accounts for 0.01% of the portfolio, ranked #820.

Barclays first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $120M in Q3 2023. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Barclays held 426,256 shares of Zimmer Biomet worth $38.5M as of Q1 2026.
  • Barclays sold 31,773 Zimmer Biomet shares in Q1 2026, an estimated $2.92M.
  • Zimmer Biomet made up 0.01% of Barclays's portfolio in Q1 2026, its #820 holding.
  • Barclays first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Zimmer Biomet position peaked at $120M in Q3 2023.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.